Horizon Pharma Inc. (NASDAQ:HZNP) has been assigned a consensus rating of “Buy” from the fourteen ratings firms that are covering the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $31.30.

A number of analysts have weighed in on the stock. Mizuho restated a “buy” rating and set a $30.00 price objective (up from $24.00) on shares of Horizon Pharma in a research note on Wednesday, August 10th. Brean Capital restated a “buy” rating and set a $30.00 price objective on shares of Horizon Pharma in a research note on Tuesday, August 9th. Morgan Stanley set a $24.00 price objective on shares of Horizon Pharma and gave the company a “hold” rating in a research note on Monday, September 12th. BMO Capital Markets restated an “outperform” rating and set a $30.00 price objective on shares of Horizon Pharma in a research note on Tuesday, September 13th. Finally, Zacks Investment Research lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 11th.

A number of institutional investors have recently modified their holdings of the stock. Credit Suisse AG increased its position in shares of Horizon Pharma by 7.1% in the third quarter. Credit Suisse AG now owns 278,617 shares of the biopharmaceutical company’s stock valued at $5,053,000 after buying an additional 18,515 shares in the last quarter. Chartwell Investment Partners LLC purchased a new position in shares of Horizon Pharma during the third quarter valued at $2,564,000. Jane Street Group LLC increased its position in shares of Horizon Pharma by 16.9% in the third quarter. Jane Street Group LLC now owns 13,797 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 1,997 shares in the last quarter. Panagora Asset Management Inc. increased its position in shares of Horizon Pharma by 24.8% in the third quarter. Panagora Asset Management Inc. now owns 614,255 shares of the biopharmaceutical company’s stock valued at $11,136,000 after buying an additional 122,100 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Horizon Pharma by 5.4% in the third quarter. D. E. Shaw & Co. Inc. now owns 977,456 shares of the biopharmaceutical company’s stock valued at $17,721,000 after buying an additional 49,942 shares in the last quarter. 87.79% of the stock is currently owned by institutional investors and hedge funds.

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 20.86 on Friday. Horizon Pharma has a 52-week low of $13.05 and a 52-week high of $23.44. The stock has a 50 day moving average of $18.14 and a 200 day moving average of $18.18. The company’s market cap is $3.36 billion.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.07. The business earned $273.70 million during the quarter, compared to analyst estimates of $270.04 million. Horizon Pharma had a negative net margin of 1.34% and a positive return on equity of 22.73%. Horizon Pharma’s revenue was up 20.8% compared to the same quarter last year. During the same period last year, the business earned $0.70 EPS. On average, equities research analysts expect that Horizon Pharma will post $2.02 EPS for the current year.

Horizon Pharma Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

5 Day Chart for NASDAQ:HZNP

Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.